vs

Side-by-side financial comparison of CABOT CORP (CBT) and Teradyne (TER). Click either name above to swap in a different company.

Teradyne is the larger business by last-quarter revenue ($1.3B vs $849.0M, roughly 1.5× CABOT CORP). Teradyne runs the higher net margin — 31.1% vs 8.6%, a 22.5% gap on every dollar of revenue. On growth, Teradyne posted the faster year-over-year revenue change (87.0% vs -11.1%). Over the past eight quarters, Teradyne's revenue compounded faster (32.6% CAGR vs -8.7%).

Cabot Corporation is an American specialty chemicals and performance materials company headquartered in Boston, Massachusetts. The company operates in over 20 countries with 36 manufacturing plants, eight research and development facilities, and 28 sales offices.

Teradyne, Inc. is an American automatic test equipment (ATE) designer and manufacturer based in North Reading, Massachusetts. Its high-profile customers include Samsung, Qualcomm, Intel, Analog Devices, Texas Instruments and IBM.

CBT vs TER — Head-to-Head

Bigger by revenue
TER
TER
1.5× larger
TER
$1.3B
$849.0M
CBT
Growing faster (revenue YoY)
TER
TER
+98.1% gap
TER
87.0%
-11.1%
CBT
Higher net margin
TER
TER
22.5% more per $
TER
31.1%
8.6%
CBT
Faster 2-yr revenue CAGR
TER
TER
Annualised
TER
32.6%
-8.7%
CBT

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
CBT
CBT
TER
TER
Revenue
$849.0M
$1.3B
Net Profit
$73.0M
$398.9M
Gross Margin
24.9%
60.9%
Operating Margin
15.2%
36.9%
Net Margin
8.6%
31.1%
Revenue YoY
-11.1%
87.0%
Net Profit YoY
-21.5%
EPS (diluted)
$1.37
$2.53

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CBT
CBT
TER
TER
Q1 26
$1.3B
Q4 25
$849.0M
$1.1B
Q3 25
$899.0M
$769.2M
Q2 25
$923.0M
$651.8M
Q1 25
$936.0M
$685.7M
Q4 24
$955.0M
$752.9M
Q3 24
$1.0B
$737.3M
Q2 24
$1.0B
$729.9M
Net Profit
CBT
CBT
TER
TER
Q1 26
$398.9M
Q4 25
$73.0M
$257.2M
Q3 25
$43.0M
$119.6M
Q2 25
$101.0M
$78.4M
Q1 25
$94.0M
$98.9M
Q4 24
$93.0M
$146.3M
Q3 24
$137.0M
$145.6M
Q2 24
$109.0M
$186.3M
Gross Margin
CBT
CBT
TER
TER
Q1 26
60.9%
Q4 25
24.9%
57.2%
Q3 25
24.5%
58.4%
Q2 25
26.4%
57.2%
Q1 25
25.7%
60.6%
Q4 24
24.6%
59.4%
Q3 24
24.0%
59.2%
Q2 24
25.2%
58.3%
Operating Margin
CBT
CBT
TER
TER
Q1 26
36.9%
Q4 25
15.2%
27.1%
Q3 25
15.2%
18.9%
Q2 25
18.1%
13.9%
Q1 25
17.3%
17.6%
Q4 24
16.2%
20.4%
Q3 24
15.0%
20.6%
Q2 24
16.9%
28.8%
Net Margin
CBT
CBT
TER
TER
Q1 26
31.1%
Q4 25
8.6%
23.7%
Q3 25
4.8%
15.5%
Q2 25
10.9%
12.0%
Q1 25
10.0%
14.4%
Q4 24
9.7%
19.4%
Q3 24
13.7%
19.8%
Q2 24
10.7%
25.5%
EPS (diluted)
CBT
CBT
TER
TER
Q1 26
$2.53
Q4 25
$1.37
$1.62
Q3 25
$0.80
$0.75
Q2 25
$1.86
$0.49
Q1 25
$1.69
$0.61
Q4 24
$1.67
$0.89
Q3 24
$2.41
$0.89
Q2 24
$1.94
$1.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CBT
CBT
TER
TER
Cash + ST InvestmentsLiquidity on hand
$230.0M
$241.9M
Total DebtLower is stronger
$0
Stockholders' EquityBook value
$1.6B
Total Assets
$3.8B
$4.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CBT
CBT
TER
TER
Q1 26
$241.9M
Q4 25
$230.0M
$293.8M
Q3 25
$258.0M
$272.7M
Q2 25
$239.0M
$339.3M
Q1 25
$213.0M
$475.6M
Q4 24
$183.0M
$553.4M
Q3 24
$223.0M
$510.0M
Q2 24
$197.0M
$421.9M
Total Debt
CBT
CBT
TER
TER
Q1 26
$0
Q4 25
Q3 25
$1.1B
Q2 25
Q1 25
Q4 24
Q3 24
$1.1B
Q2 24
Stockholders' Equity
CBT
CBT
TER
TER
Q1 26
Q4 25
$1.6B
$2.8B
Q3 25
$1.6B
$2.7B
Q2 25
$1.5B
$2.8B
Q1 25
$1.4B
$2.8B
Q4 24
$1.4B
$2.8B
Q3 24
$1.4B
$2.9B
Q2 24
$1.3B
$2.7B
Total Assets
CBT
CBT
TER
TER
Q1 26
$4.4B
Q4 25
$3.8B
$4.2B
Q3 25
$3.8B
$4.0B
Q2 25
$3.8B
$3.8B
Q1 25
$3.8B
$3.7B
Q4 24
$3.6B
$3.7B
Q3 24
$3.7B
$3.8B
Q2 24
$3.6B
$3.6B
Debt / Equity
CBT
CBT
TER
TER
Q1 26
Q4 25
Q3 25
0.70×
Q2 25
Q1 25
Q4 24
Q3 24
0.75×
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CBT
CBT
TER
TER
Operating Cash FlowLast quarter
$126.0M
$265.1M
Free Cash FlowOCF − Capex
$57.0M
FCF MarginFCF / Revenue
6.7%
Capex IntensityCapex / Revenue
8.1%
Cash ConversionOCF / Net Profit
1.73×
0.66×
TTM Free Cash FlowTrailing 4 quarters
$401.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CBT
CBT
TER
TER
Q1 26
$265.1M
Q4 25
$126.0M
$281.6M
Q3 25
$219.0M
$49.0M
Q2 25
$249.0M
$182.1M
Q1 25
$73.0M
$161.6M
Q4 24
$124.0M
$282.6M
Q3 24
$204.0M
$166.3M
Q2 24
$207.0M
$216.1M
Free Cash Flow
CBT
CBT
TER
TER
Q1 26
Q4 25
$57.0M
$218.8M
Q3 25
$155.0M
$2.4M
Q2 25
$188.0M
$131.7M
Q1 25
$1.0M
$97.6M
Q4 24
$47.0M
$225.2M
Q3 24
$112.0M
$114.4M
Q2 24
$155.0M
$171.2M
FCF Margin
CBT
CBT
TER
TER
Q1 26
Q4 25
6.7%
20.2%
Q3 25
17.2%
0.3%
Q2 25
20.4%
20.2%
Q1 25
0.1%
14.2%
Q4 24
4.9%
29.9%
Q3 24
11.2%
15.5%
Q2 24
15.3%
23.5%
Capex Intensity
CBT
CBT
TER
TER
Q1 26
Q4 25
8.1%
5.8%
Q3 25
7.1%
6.1%
Q2 25
6.6%
7.7%
Q1 25
7.7%
9.3%
Q4 24
8.1%
7.6%
Q3 24
9.2%
7.0%
Q2 24
5.1%
6.1%
Cash Conversion
CBT
CBT
TER
TER
Q1 26
0.66×
Q4 25
1.73×
1.09×
Q3 25
5.09×
0.41×
Q2 25
2.47×
2.32×
Q1 25
0.78×
1.63×
Q4 24
1.33×
1.93×
Q3 24
1.49×
1.14×
Q2 24
1.90×
1.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CBT
CBT

Reinforcement Materials$520.0M61%
Performance Chemicals$300.0M35%
Shipping And Handling$25.0M3%
Other Products And Services$4.0M0%

TER
TER

Segment breakdown not available.

Related Comparisons